L-arginine for the treatment of centrally obese subjects: A pilot study

Ryan T Hurt, Jon Owen Ebbert, Darrell R. Schroeder, Ivana T Croghan, Brent A Bauer, Stephen A. McClave, John M. Miles, Craig J. McClain

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Visceral adiposity has been linked to higher rates of cardiometabolic risk than other types of adiposity. Waist circumference (WC) is the best anthropomorphic surrogate of visceral adiposity. Reductions in central adiposity may decrease cardiovascular risk. Animal studies have demonstrated that L-arginine reduces visceral adiposity and fat mass. The primary aim of our study was to assess the efficacy of L-arginine for reducing central adiposity in nondiabetic obese subjects. Secondary aims were to assess the efficacy of L-arginine for decreasing body mass index (BMI), waist-to-hip ratio (WHR), and weight. Materials and Methods: Female subjects (n = 20) were included if they: were ≥ 18 years and ≤ 40 years of age, had a BMI of ≥ 30 and ≤ 40 kg/m2, had a WC ≥ 89 cm. Subjects received 3 g of L-arginine three times a day for 12 weeks and were counseled on lifestyle modification. Results: Overall, L-arginine was well tolerated with no clinically significant adverse events. Serum L-arginine levels were significantly increased from baseline at both 6 and 12 weeks (p < .05). WC (mean ± SD) decreased from 115.6 ± 12.7 cm at baseline to 109.2 ± 11.7 cm at 12 weeks (p = .0004). Weight (mean ± SD) decreased from 98.6 ± 19.7 kg at baseline to 95.7 ± 18.6 kg at 12 weeks (p = .015). Significant reductions from baseline were also observed in BMI and WHR. Conclusions: L-Arginine may be effective at reducing central adiposity in obese patients.

Original languageEnglish (US)
Pages (from-to)40-52
Number of pages13
JournalJournal of Dietary Supplements
Volume11
Issue number1
DOIs
StatePublished - Mar 2014

Fingerprint

Adiposity
adiposity
arginine
Arginine
waist circumference
Waist Circumference
body mass index
waist-to-hip ratio
Body Mass Index
Waist-Hip Ratio
Weights and Measures
Intra-Abdominal Fat
lifestyle
Life Style
lipids
Serum
animals

Keywords

  • L-arginine
  • Obesity
  • Supplement
  • Weight loss

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics
  • Pharmacology (medical)

Cite this

L-arginine for the treatment of centrally obese subjects : A pilot study. / Hurt, Ryan T; Ebbert, Jon Owen; Schroeder, Darrell R.; Croghan, Ivana T; Bauer, Brent A; McClave, Stephen A.; Miles, John M.; McClain, Craig J.

In: Journal of Dietary Supplements, Vol. 11, No. 1, 03.2014, p. 40-52.

Research output: Contribution to journalArticle

Hurt, Ryan T ; Ebbert, Jon Owen ; Schroeder, Darrell R. ; Croghan, Ivana T ; Bauer, Brent A ; McClave, Stephen A. ; Miles, John M. ; McClain, Craig J. / L-arginine for the treatment of centrally obese subjects : A pilot study. In: Journal of Dietary Supplements. 2014 ; Vol. 11, No. 1. pp. 40-52.
@article{a6767d30720a43c49390cdd7631baebe,
title = "L-arginine for the treatment of centrally obese subjects: A pilot study",
abstract = "Background: Visceral adiposity has been linked to higher rates of cardiometabolic risk than other types of adiposity. Waist circumference (WC) is the best anthropomorphic surrogate of visceral adiposity. Reductions in central adiposity may decrease cardiovascular risk. Animal studies have demonstrated that L-arginine reduces visceral adiposity and fat mass. The primary aim of our study was to assess the efficacy of L-arginine for reducing central adiposity in nondiabetic obese subjects. Secondary aims were to assess the efficacy of L-arginine for decreasing body mass index (BMI), waist-to-hip ratio (WHR), and weight. Materials and Methods: Female subjects (n = 20) were included if they: were ≥ 18 years and ≤ 40 years of age, had a BMI of ≥ 30 and ≤ 40 kg/m2, had a WC ≥ 89 cm. Subjects received 3 g of L-arginine three times a day for 12 weeks and were counseled on lifestyle modification. Results: Overall, L-arginine was well tolerated with no clinically significant adverse events. Serum L-arginine levels were significantly increased from baseline at both 6 and 12 weeks (p < .05). WC (mean ± SD) decreased from 115.6 ± 12.7 cm at baseline to 109.2 ± 11.7 cm at 12 weeks (p = .0004). Weight (mean ± SD) decreased from 98.6 ± 19.7 kg at baseline to 95.7 ± 18.6 kg at 12 weeks (p = .015). Significant reductions from baseline were also observed in BMI and WHR. Conclusions: L-Arginine may be effective at reducing central adiposity in obese patients.",
keywords = "L-arginine, Obesity, Supplement, Weight loss",
author = "Hurt, {Ryan T} and Ebbert, {Jon Owen} and Schroeder, {Darrell R.} and Croghan, {Ivana T} and Bauer, {Brent A} and McClave, {Stephen A.} and Miles, {John M.} and McClain, {Craig J.}",
year = "2014",
month = "3",
doi = "10.3109/19390211.2013.859216",
language = "English (US)",
volume = "11",
pages = "40--52",
journal = "Journal of Dietary Supplements",
issn = "1939-0211",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - L-arginine for the treatment of centrally obese subjects

T2 - A pilot study

AU - Hurt, Ryan T

AU - Ebbert, Jon Owen

AU - Schroeder, Darrell R.

AU - Croghan, Ivana T

AU - Bauer, Brent A

AU - McClave, Stephen A.

AU - Miles, John M.

AU - McClain, Craig J.

PY - 2014/3

Y1 - 2014/3

N2 - Background: Visceral adiposity has been linked to higher rates of cardiometabolic risk than other types of adiposity. Waist circumference (WC) is the best anthropomorphic surrogate of visceral adiposity. Reductions in central adiposity may decrease cardiovascular risk. Animal studies have demonstrated that L-arginine reduces visceral adiposity and fat mass. The primary aim of our study was to assess the efficacy of L-arginine for reducing central adiposity in nondiabetic obese subjects. Secondary aims were to assess the efficacy of L-arginine for decreasing body mass index (BMI), waist-to-hip ratio (WHR), and weight. Materials and Methods: Female subjects (n = 20) were included if they: were ≥ 18 years and ≤ 40 years of age, had a BMI of ≥ 30 and ≤ 40 kg/m2, had a WC ≥ 89 cm. Subjects received 3 g of L-arginine three times a day for 12 weeks and were counseled on lifestyle modification. Results: Overall, L-arginine was well tolerated with no clinically significant adverse events. Serum L-arginine levels were significantly increased from baseline at both 6 and 12 weeks (p < .05). WC (mean ± SD) decreased from 115.6 ± 12.7 cm at baseline to 109.2 ± 11.7 cm at 12 weeks (p = .0004). Weight (mean ± SD) decreased from 98.6 ± 19.7 kg at baseline to 95.7 ± 18.6 kg at 12 weeks (p = .015). Significant reductions from baseline were also observed in BMI and WHR. Conclusions: L-Arginine may be effective at reducing central adiposity in obese patients.

AB - Background: Visceral adiposity has been linked to higher rates of cardiometabolic risk than other types of adiposity. Waist circumference (WC) is the best anthropomorphic surrogate of visceral adiposity. Reductions in central adiposity may decrease cardiovascular risk. Animal studies have demonstrated that L-arginine reduces visceral adiposity and fat mass. The primary aim of our study was to assess the efficacy of L-arginine for reducing central adiposity in nondiabetic obese subjects. Secondary aims were to assess the efficacy of L-arginine for decreasing body mass index (BMI), waist-to-hip ratio (WHR), and weight. Materials and Methods: Female subjects (n = 20) were included if they: were ≥ 18 years and ≤ 40 years of age, had a BMI of ≥ 30 and ≤ 40 kg/m2, had a WC ≥ 89 cm. Subjects received 3 g of L-arginine three times a day for 12 weeks and were counseled on lifestyle modification. Results: Overall, L-arginine was well tolerated with no clinically significant adverse events. Serum L-arginine levels were significantly increased from baseline at both 6 and 12 weeks (p < .05). WC (mean ± SD) decreased from 115.6 ± 12.7 cm at baseline to 109.2 ± 11.7 cm at 12 weeks (p = .0004). Weight (mean ± SD) decreased from 98.6 ± 19.7 kg at baseline to 95.7 ± 18.6 kg at 12 weeks (p = .015). Significant reductions from baseline were also observed in BMI and WHR. Conclusions: L-Arginine may be effective at reducing central adiposity in obese patients.

KW - L-arginine

KW - Obesity

KW - Supplement

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=84894600647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894600647&partnerID=8YFLogxK

U2 - 10.3109/19390211.2013.859216

DO - 10.3109/19390211.2013.859216

M3 - Article

C2 - 24409974

AN - SCOPUS:84894600647

VL - 11

SP - 40

EP - 52

JO - Journal of Dietary Supplements

JF - Journal of Dietary Supplements

SN - 1939-0211

IS - 1

ER -